Related Experiment Video
Updated: Dec 18, 2025
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
14.2K
Cabozantinib as an emerging treatment for sarcoma
Patrick Schöffski1, Jean-Yves Blay2, Isabelle Ray-Coquard3
1Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
Current Opinion in Oncology
|June 17, 2020
Summary
Cabozantinib shows promise for treating rare sarcomas, including soft tissue sarcoma, GIST, osteosarcoma, and Ewing sarcoma. Further clinical evaluation is supported by preclinical and early clinical trial findings.
Area of Science:
- Oncology
- Pharmacology
Background:
- Sarcomas are rare solid tumors with limited treatment options for advanced disease.
- Cabozantinib targets kinases like MET, VEGF, and AXL, crucial in sarcoma development.
Purpose of the Study:
- To review preclinical and clinical data of cabozantinib in treating various sarcoma types.
- To assess cabozantinib's efficacy in soft tissue sarcoma, GIST, osteosarcoma, and Ewing sarcoma.
Main Methods:
- Review of preclinical studies demonstrating cabozantinib's in vitro and in vivo anti-sarcoma activity.
- Analysis of ongoing and completed prospective clinical trials involving cabozantinib for sarcoma patients.
Main Results:
- Cabozantinib inhibited growth and viability in multiple sarcoma cell lines in vitro.
- Tumor regression observed in GIST murine xenografts, including imatinib-resistant models.
- Phase 2 trials reported clinical activity in GIST, osteosarcoma, and Ewing sarcoma.
Conclusions:
- Cabozantinib exhibits promising activity against diverse sarcoma types.
- Further investigation of cabozantinib for sarcoma treatment is warranted.
More Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
02:57Targeted Cancer Therapies
8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.5K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
01:27Tumor Immunotherapy
1.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K
02:49Cancer Therapies
9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
03:03mTOR Signaling and Cancer Progression
4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.5K